Pharvaris N.V. PHVS
33.15 USD -1.18 (-3.44%)
Nov 5, 2026, 12:05 PM EST
33.15 Day range 34.66
21.02 52-week range 43.25
- YTD
- +19.46%
- 1 year
- +52.62%
- Market cap
- 2.33B
- EPS (ttm)
- -3.06
- Shares out
- 70.20M
- Forward P/E
- -11.23
- YTD return
- +19.46%
- 1-year return
- +52.62%
- Volume
- 368.16K
- Avg volume
- 811.83K
- Open
- 34.33
- Previous close
- 34.33
- Day's range
- 33.15 – 34.66
- 52-week range
- 21.02 – 43.25
- Beta
- -2.52
- Analysts
- Strong Buy
- Price target
- 57.83 (+74.4%)
- Earnings date
- Nov 11, 2026
2Y +10.25 (+44.16%)
Key statistics
- Enterprise value
- 2.12B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 7.13
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -90.36M
- Total cash
- 318.28M
- Total debt
- 673.73K
- Return on equity
- -70.46%
- Short % of float
- 4.26%
- 50-day average
- 33.56
- 200-day average
- 31.08
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 57.83 +74.4% upside
Now 33.15
- Target (low)
- 41.13
- Target (mean)
- 57.83
- Target (high)
- 79.25
Ratings (0m) 14 14 buy · 0 hold · 0 sell
- Strong buy3
- Buy11
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 11, 2026
Expected Nov 11, 2026. Consensus EPS estimate -0.71909.
Financials — quick view
PHVS Revenue — quarterly 0
PHVS Net income — quarterly -47.84M
PHVS EPS — quarterly -0.70
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2026 | Sep 30, 2026 | -0.81867 | — | — | — |
| Aug 12, 2026 | Jun 30, 2026 | -0.7467 | -0.81 | -0.06 | -8.48% |
| May 12, 2026 | Mar 31, 2026 | -0.82187 | -0.70 | +0.12 | +14.83% |
| Apr 2, 2026 | Dec 31, 2025 | -0.71462 | -0.84565 | -0.13 | -18.34% |
| Nov 12, 2025 | Sep 30, 2025 | -0.78 | -0.70 | +0.08 | +10.26% |
| Aug 12, 2025 | Jun 30, 2025 | -0.87 | -0.94 | -0.07 | -8.05% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 23, 2026 | B of A Securities | up | Neutral | Buy |
| Sep 10, 2026 | Guggenheim | main | Buy | Buy |
| Sep 9, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Sep 9, 2026 | Leerink Partners | main | Outperform | Outperform |
| Sep 9, 2026 | Wells Fargo | main | Overweight | Overweight |
| Sep 9, 2026 | RBC Capital | main | Outperform | Outperform |
About Pharvaris N.V.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Switzerland
- Website
- pharvaris.com
News
This Monolithic Power Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday 
This Hilton Hotels Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday 
Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting 
This Pentair Analyst Is No Longer Bearish; Here Are Top 2 Upgrades For Wednesday 
This Tesla Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday 
Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade 
Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade 
This Allegion Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday 
B of A Securities Upgrades Pharvaris to Buy, Maintains Price Target to $44 
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Your note
Sign in to keep a note on PHVS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ABELE STEFAN | Chief Operating Officer | Sale | Sep 14, 2026 | 39,068 |
| BJORK ELISABETH | Director | Sale | Sep 16, 2026 | 15,167 |
| GLASSMAN ROBERT R. | Director | Sale | Sep 16, 2026 | 10,500 |
| LESAGE ANNE SIMONNE J PH.D. | Officer | Sale | Sep 16, 2026 | 0 |
| LU PENG | President | Conversion of Exercise of derivative security | Sep 21, 2026 | 110,261 |
| MODIG BERNDT B.A.E | Chief Executive Officer | Conversion of Exercise of derivative security | Sep 16, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 10.04% | 6,565,272 | 225.39M | Jun 29, 2026 |
| General Atlantic, L.P. | 10.02% | 6,550,757 | 224.89M | Jun 29, 2026 |
| Foresite Capital Management IV, LLC | 7.31% | 4,778,581 | 164.05M | Jun 29, 2026 |
| venBio Partners LLC | 7.10% | 4,643,430 | 159.41M | Jun 29, 2026 |
| Viking Global Investors, L.P. | 5.59% | 3,653,310 | 125.42M | Jun 29, 2026 |
| Eqt Fund Management S.a R.l. | 5.24% | 3,424,609 | 117.57M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.10% | 1,373,193 | 47.14M | Aug 30, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 1.78% | 1,165,414 | 40.01M | Jul 30, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1.22% | 800,000 | 27.46M | Aug 30, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 0.99% | 644,591 | 22.13M | Jul 30, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Health Care Fund | 0.61% | 400,000 | 13.73M | Aug 30, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 0.61% | 399,479 | 13.71M | Aug 30, 2026 |